Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 9.06B +171.0% |
| Revenue (ttm) | 74.06M -64.4% |
| Net Income | -114.71M |
| EPS | -1.79 |
| Shares Out | 64.31M |
| PE Ratio | n/a |
| Forward PE | 40.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,374,228 |
| Open | 132.59 |
| Previous Close | 131.50 |
| Day's Range | 130.69 - 141.08 |
| 52-Week Range | 49.38 - 141.08 |
| Beta | 1.79 |
| Analysts | Strong Buy |
| Price Target | 120.54 (-14.42%) |
| Earnings Date | Aug 5, 2026 |
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class or... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $120.54, which is a decrease of -14.42% from the latest price.
News
Protagonist Therapeutics price target raised to $145 from $121 at Truist
Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $145 from $121 and keeps a Buy rating on the shares. The firm remains bullish on the broader Icotyde…
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accor...
Protagonist Therapeutics Transcript: AGM 2026
The meeting covered board introductions, four key proposals, and voting procedures. All proposals—including director elections, executive compensation, auditor ratification, and the equity incentive plan—were approved. Voting results will be filed with the SEC.
Protagonist Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing as a commercial-stage biotech with strong financials, highlighted by Icotyde's successful launch and anticipated Rusfertide approval. Its robust, de-risked pipeline includes innovative oral peptides for I&I and obesity, with strategic partnerships and shareholder rewards planned.
Protagonist Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Strong royalty streams from major partnerships and a robust, de-risked pipeline support self-funded R&D and potential share buybacks. ICOTYDE is positioned for major growth, while rusfertide's opt-out deal secures significant payments and high royalties. Multiple innovative programs advance toward key milestones.
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will...
Protagonist Therapeutics Slides: Company presentation
Protagonist Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics price target raised to $130 from $125 at Citi
Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $130 from $125 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics (PTGX) to $137 from $120 and keeps an Outperform rating on the shares. Protagonist Therapeutics is expecte...
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $97 and keeps a Neutral rating on the shares. The price target increase is driven mainly…
Protagonist Therapeutics management to meet virtually with Clear Street
Virtual Meeting to be held on May 12-13 hosted by Clear Street.
Protagonist Therapeutics participates in a conference call with JPMorgan
Conference call with management will be held on May 6 at 2 pm hosted by JPMorgan.Webcast Link
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible ...
Protagonist Therapeutics Earnings release: Q1 2026
Protagonist Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Protagonist Therapeutics Quarterly report: Q1 2026
Protagonist Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
Protagonist Therapeutics (PTGX) announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its worldwide license and collaboration agreement with…
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 millio...
Protagonist Therapeutics Proxy statement: Proxy filing
Protagonist Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Protagonist Therapeutics Proxy statement: Proxy filing
Protagonist Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. The firm is citing strong…
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. Following J&J’s (JNJ) commentary on…
Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $116 from $104 and keeps a Buy rating on the shares. Following management meetings, the…
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results fur...
Protagonist price target raised to $110 from $107 at Leerink
Leerink analyst Faisal Khurshid raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $107 and keeps an Outperform rating on the shares. The firm is “impressed” with…